PF-05381941

Cat. No.: HY-120823

CAS No.: 1474022-02-0

Molecular Formula: $C_{27}H_{26}N_6O_2$

Molecular Weight: 466.53

Target: MAP3K; p38 MAPK

Pathway: MAPK/ERK Pathway

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (214.35 mM; Need ultrasonic)

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	2.1435 mL	10.7174 mL	21.4348 mL
5 mM	0.4287 mL	2.1435 mL	4.2870 mL
10 mM	0.2143 mL	1.0717 mL	2.1435 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (5.36 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (5.36 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 1.39 mg/mL (2.98 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

PF-05381941 is a potent dual inhibitor of TAK1/p38α, with IC_{50}s of 156 and186 nM, respectively[1].

IC_{50} & Target

p38α	TAK1
186 nM (IC_{50})	156 nM (IC_{50})

In Vitro

PF-05381941 inhibits LPS-stimulated release of TNF-αfrom human peripheralmononuclear (PMN) cells with an IC_{50} of 8 nM[1]
.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Kilty I, et al. TAK1 inhibition in the DFG-out conformation. Chem Biol Drug Des. 2013;82(5):500-505.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA